Tonix Pharmaceuticals Holding Corp. (TNXP)

Price$12.29

Value ScoreB

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-37.09%

Price vs S&P 500 (4W)-14.31%

VGM Score60.30

Market Capitalization$196.55M

All Metrics

Book Value / Share (Quarterly)$15.99

P/TBV (Annual)0.82x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-9.20

Price vs S&P 500 (YTD)-32.00%

Gross Margin (TTM)58.56%

Net Profit Margin (TTM)-839.52%

EPS (TTM)$-14.34

10-Day Avg Trading Volume0.49M

EPS Excl Extra (TTM)$-14.34

EPS (Annual)$-14.57

ROI (Annual)-50.59%

Gross Margin (Annual)49.34%

Cash / Share (Quarterly)$13.06

Revenue Growth QoQ (YoY)183.16%

ROA (Last FY)-44.75%

Revenue Growth TTM (YoY)74.84%

EBITD / Share (TTM)$-14.28

ROE (5Y Avg)-69.94%

Operating Margin (TTM)-861.16%

Cash Flow / Share (Annual)$-8.07

P/B Ratio0.87x

P/B Ratio (Quarterly)0.86x

Net Income / Employee (Annual)$-873,400

EV / Revenue (TTM)0.63x

Net Interest Coverage (TTM)-2.39x

ROA (TTM)-60.47%

EPS Incl Extra (Annual)$-14.57

Current Ratio (Annual)7.42x

Quick Ratio (Quarterly)6.59x

3-Month Avg Trading Volume0.41M

52-Week Price Return-70.66%

Revenue / Employee (TTM)$123,600

Tangible BV / Share (Quarterly)$15.98

P/S Ratio (Annual)15.00x

Asset Turnover (Annual)0.05x

52-Week High$69.97

EPS Excl Extra (Annual)$-14.57

CapEx CAGR (5Y)-17.01%

Tangible BV CAGR (5Y)91.96%

26-Week Price Return-21.16%

Quick Ratio (Annual)6.99x

13-Week Price Return-14.55%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.99x

Enterprise Value$11.08M

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-26.22%

Revenue / Employee (Annual)$92,300

Pretax Margin (Annual)-946.22%

Cash / Share (Annual)$16.24

3-Month Return Std Dev81.05%

Net Income / Employee (TTM)$-1,037,900

ROE (Last FY)-50.59%

Net Interest Coverage (Annual)-421.14x

EPS Basic Excl Extra (Annual)$-14.57

Receivables Turnover (TTM)2.89x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-14.34

ROI (TTM)-67.65%

P/S Ratio (TTM)11.20x

Revenue / Share (Annual)$1.54

Tangible BV / Share (Annual)$19.16

Price vs S&P 500 (52W)-98.86%

Year-to-Date Return-21.06%

5-Day Price Return-3.45%

EPS Normalized (Annual)$-14.57

ROA (5Y Avg)-57.45%

Net Profit Margin (Annual)-946.22%

Month-to-Date Return-4.64%

Cash Flow / Share (TTM)$-10.41

EBITD / Share (Annual)$-14.79

Operating Margin (Annual)-975.01%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-67.27%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-14.34

P/TBV (Quarterly)0.86x

P/B Ratio (Annual)0.81x

Inventory Turnover (TTM)1.24x

Pretax Margin (TTM)-839.52%

Book Value / Share (Annual)$19.17

Price vs S&P 500 (13W)-24.30%

Beta1.70x

Revenue / Share (TTM)$1.28

ROE (TTM)-67.65%

52-Week Low$11.60

vGradeB

gGradeA

mGradeD

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-2.93est. -2.48

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
TNXPTonix Pharmaceuticals Holding Corp.	B	A	D	$12.29
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Tonix Pharmaceuticals is a commercial-stage biotech company developing treatments for CNS disorders and immunological conditions. Its approved product TONMYA treats fibromyalgia, while marketed migraine medications Zembrace SymTouch and Tosymra provide current revenue. The company is expanding TONMYA into depression and acute stress disorder through clinical trials and advancing a pipeline including TNX-4800 for Lyme disease prevention and TNX-1500 for transplant rejection prevention.